HUMA vs. LLY

Last updated Apr 1, 2026

Compare and contrast key facts about Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY).

Performance

HUMA vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

HUMA vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
HUMA Humacyte, Inc.	-36.83%	-80.98%	77.82%	34.60%	-70.90%	-33.85%
LLY Eli Lilly and Company	-14.27%	40.25%	33.30%	60.91%	34.26%	6.05%

Fundamentals

Market Cap HUMA : $95.96M LLY : $825.96B
EPS HUMA : -$0.26 LLY : $22.96
PS Ratio HUMA : 46.83 LLY : 12.68
PB Ratio HUMA : 30.86 LLY : 31.13
Total Revenue (TTM) HUMA : $2.04M LLY : $65.18B
Gross Profit (TTM) HUMA : -$2.74M LLY : $54.62B
EBITDA (TTM) HUMA : -$33.15M LLY : $27.94B

Returns By Period

In the year-to-date period, HUMA achieves a -36.83% return, which is significantly lower than LLY's -14.27% return.

HUMA

• 1D: 5.60%
• 1M: -45.59%
• YTD: -36.83%
• 6M: -65.13%
• 1Y: -64.42%
• 3Y*: -41.88%
• 5Y*: —
• 10Y*: —

LLY

• 1D: 3.74%
• 1M: -12.57%
• YTD: -14.27%
• 6M: 20.93%
• 1Y: 12.19%
• 3Y*: 39.90%
• 5Y*: 39.16%
• 10Y*: 30.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HUMA vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HUMA

HUMA Risk / Return Rank: 15
HUMA Sharpe Ratio Rank: 17
HUMA Sortino Ratio Rank: 19
HUMA Omega Ratio Rank: 20
HUMA Calmar Ratio Rank: 9
HUMA Martin Ratio Rank: 8

LLY

LLY Risk / Return Rank: 51
LLY Sharpe Ratio Rank: 53
LLY Sortino Ratio Rank: 48
LLY Omega Ratio Rank: 49
LLY Calmar Ratio Rank: 53
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HUMA vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HUMA	LLY	Difference
Sharpe ratio Return per unit of total volatility	-0.56	0.29	-0.85
Sortino ratio Return per unit of downside risk	-0.48	0.69	-1.17
Omega ratio Gain probability vs. loss probability	0.94	1.10	-0.15
Calmar ratio Return relative to maximum drawdown	-0.87	0.42	-1.29
Martin ratio Return relative to average drawdown	-1.58	1.02	-2.60
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HUMA vs. LLY - Sharpe Ratio Comparison

The current HUMA Sharpe Ratio is -0.56, which is lower than the LLY Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of HUMA and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HUMA	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.56	0.29	-0.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.23	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.04	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.49	0.56	-1.05

Correlation

The correlation between HUMA and LLY is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HUMA vs. LLY - Dividend Comparison

HUMA has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
HUMA Humacyte, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.68%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

HUMA vs. LLY - Drawdown Comparison

The maximum HUMA drawdown since its inception was -96.62%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for HUMA and LLY.

Drawdown Indicators

	HUMA	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-96.62%	-68.24%	-28.38%
Max Drawdown (1Y) Largest decline over 1 year	-79.26%	-30.26%	-49.00%
Max Drawdown (5Y) Largest decline over 5 years	—	-34.48%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-96.43%	-17.00%	-79.43%
Average Drawdown Average peak-to-trough decline	-75.57%	-19.25%	-56.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	43.81%	12.39%	+31.42%

Volatility

HUMA vs. LLY - Volatility Comparison

Humacyte, Inc. (HUMA) has a higher volatility of 37.44% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that HUMA's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HUMA	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	37.44%	9.04%	+28.40%
Volatility (6M) Calculated over the trailing 6-month period	83.33%	26.21%	+57.12%
Volatility (1Y) Calculated over the trailing 1-year period	116.55%	42.44%	+74.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	96.68%	32.14%	+64.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.68%	29.80%	+66.88%

Financials